Assessment of the Relationship between Hypnotics and Delirium Using the Japanese Adverse Drug Event Report (JADER) Database
The Japanese Adverse Drug Event Report (JADER) database was used to examine the risk of delirium and the time of its onset with various hypnotics, including 10 benzodiazepines (BZDs), 3 non-benzodiazepines (non-BZDs), 1 melatonin receptor agonist (MRTA), and 1 orexin receptor inhibitor (OXRI). Data...
Saved in:
| Published in | YAKUGAKU ZASSHI Vol. 138; no. 7; pp. 985 - 990 |
|---|---|
| Main Authors | , , , , , |
| Format | Journal Article |
| Language | English Japanese |
| Published |
Japan
The Pharmaceutical Society of Japan
01.07.2018
Pharmaceutical Society of Japan |
| Subjects | |
| Online Access | Get full text |
| ISSN | 0031-6903 1347-5231 1347-5231 |
| DOI | 10.1248/yakushi.17-00221 |
Cover
| Abstract | The Japanese Adverse Drug Event Report (JADER) database was used to examine the risk of delirium and the time of its onset with various hypnotics, including 10 benzodiazepines (BZDs), 3 non-benzodiazepines (non-BZDs), 1 melatonin receptor agonist (MRTA), and 1 orexin receptor inhibitor (OXRI). Data entered in the JADER database between April 1, 2004 and February 1, 2016 were analyzed. The index for safety signal detection, the reporting odds ratio (ROR), was the odds ratio for adverse drug reaction reporting. The ROR for each drug was calculated; a signal was considered present if the lower bound of the 95% confidence interval of the ROR was greater than 1. The time to onset of delirium was calculated for drugs for which the number of days from the start of drug administration to delirium onset was reported. During the period examined in the analysis, a total of 621114 adverse drug reaction reports were seen, and the total number of delirium reports was 1417 after redundant cases were excluded. A signal was detected for 5 of the 10 BZDs and all 3 non-BZDs, with no signal for the MRTA and the OXRI. The time of delirium onset varied widely even for drugs classified as being in the same action duration group, and no correlation was seen for delirium onset time. The results of this study suggested that delirium risk varies depending on the hypnotic. Thus, hypnotics can be selected according to their delirium risk. |
|---|---|
| AbstractList | The Japanese Adverse Drug Event Report (JADER) database was used to examine the risk of delirium and the time of its onset with various hypnotics, including 10 benzodiazepines (BZDs), 3 non-benzodiazepines (non-BZDs), 1 melatonin receptor agonist (MRTA), and 1 orexin receptor inhibitor (OXRI). Data entered in the JADER database between April 1, 2004 and February 1, 2016 were analyzed. The index for safety signal detection, the reporting odds ratio (ROR), was the odds ratio for adverse drug reaction reporting. The ROR for each drug was calculated; a signal was considered present if the lower bound of the 95% confidence interval of the ROR was greater than 1. The time to onset of delirium was calculated for drugs for which the number of days from the start of drug administration to delirium onset was reported. During the period examined in the analysis, a total of 621114 adverse drug reaction reports were seen, and the total number of delirium reports was 1417 after redundant cases were excluded. A signal was detected for 5 of the 10 BZDs and all 3 non-BZDs, with no signal for the MRTA and the OXRI. The time of delirium onset varied widely even for drugs classified as being in the same action duration group, and no correlation was seen for delirium onset time. The results of this study suggested that delirium risk varies depending on the hypnotic. Thus, hypnotics can be selected according to their delirium risk. The Japanese Adverse Drug Event Report (JADER) database was used to examine the risk of delirium and the time of its onset with various hypnotics, including 10 benzodiazepines (BZDs), 3 non-benzodiazepines (non-BZDs), 1 melatonin receptor agonist (MRTA), and 1 orexin receptor inhibitor (OXRI). Data entered in the JADER database between April 1, 2004 and February 1, 2016 were analyzed. The index for safety signal detection, the reporting odds ratio (ROR), was the odds ratio for adverse drug reaction reporting. The ROR for each drug was calculated; a signal was considered present if the lower bound of the 95% confidence interval of the ROR was greater than 1. The time to onset of delirium was calculated for drugs for which the number of days from the start of drug administration to delirium onset was reported. During the period examined in the analysis, a total of 621114 adverse drug reaction reports were seen, and the total number of delirium reports was 1417 after redundant cases were excluded. A signal was detected for 5 of the 10 BZDs and all 3 non-BZDs, with no signal for the MRTA and the OXRI. The time of delirium onset varied widely even for drugs classified as being in the same action duration group, and no correlation was seen for delirium onset time. The results of this study suggested that delirium risk varies depending on the hypnotic. Thus, hypnotics can be selected according to their delirium risk. The Japanese Adverse Drug Event Report (JADER) database was used to examine the risk of delirium and the time of its onset with various hypnotics, including 10 benzodiazepines (BZDs), 3 non-benzodiazepines (non-BZDs), 1 melatonin receptor agonist (MRTA), and 1 orexin receptor inhibitor (OXRI). Data entered in the JADER database between April 1, 2004 and February 1, 2016 were analyzed. The index for safety signal detection, the reporting odds ratio (ROR), was the odds ratio for adverse drug reaction reporting. The ROR for each drug was calculated; a signal was considered present if the lower bound of the 95% confidence interval of the ROR was greater than 1. The time to onset of delirium was calculated for drugs for which the number of days from the start of drug administration to delirium onset was reported. During the period examined in the analysis, a total of 621114 adverse drug reaction reports were seen, and the total number of delirium reports was 1417 after redundant cases were excluded. A signal was detected for 5 of the 10 BZDs and all 3 non-BZDs, with no signal for the MRTA and the OXRI. The time of delirium onset varied widely even for drugs classified as being in the same action duration group, and no correlation was seen for delirium onset time. The results of this study suggested that delirium risk varies depending on the hypnotic. Thus, hypnotics can be selected according to their delirium risk. |
| Author | Suzuki, Shinichiro Hidaka, Shinji Imai, Toru Kikuchi, Norikazu Hazama, Katsuyuki Yoshida, Yoshikazu |
| Author_xml | – sequence: 1 fullname: Imai, Toru organization: Department of Pharmacy, Nihon University Itabashi Hospital – sequence: 1 fullname: Yoshida, Yoshikazu organization: Department of Pharmacy, Nihon University Itabashi Hospital – sequence: 1 fullname: Hazama, Katsuyuki organization: Department of Pharmacy, Nihon University Itabashi Hospital – sequence: 1 fullname: Kikuchi, Norikazu organization: Department of Pharmacy, Nihon University Hospital – sequence: 1 fullname: Suzuki, Shinichiro organization: Department of Pharmacy, Nihon University Itabashi Hospital – sequence: 1 fullname: Hidaka, Shinji organization: Department of Pharmaceutical Regulatory Science, School of Pharmacy, Nihon University |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/29962478$$D View this record in MEDLINE/PubMed |
| BookMark | eNqNkktvEzEUhS1UREPpnhXysl1M8WMenmXUhIaqElJE15bHcydxcTyD7WkV8edxHg0SC8Tm2ovznXvvsd-jM9c7QOgjJTeU5eLzVv0Yw9rc0CojhDH6Bk0oz6usYJyeoQkhnGZlTfg5ugzBNDsNYwUV79A5q-uS5ZWYoF_TECCEDbiI-w7HNeAlWBVN75L3gBuILwAOL7aD66PRASvX4hlY4824wY_BuNWeuleDchAAT9tn8Omc-XGF58874yUMvY_46n46my-v8UxF1agAH9DbTtkAl8fzAj1-mX-_XWQP3-6-3k4fMl0KETOaV1xATgpNipbrgrCmEUXe0pK3eU21YqrRdSF4W4HKK4BCqDovu46VpFN1zS8QPfiOblDbF2WtHLzZKL-VlMhdlvKYpaSV3GeZmKsDM_j-5wghyo0JGqxNS_ZjkIyUvKJUsCJJPx2lY7OB9uT9GnISkINA-z4ED93_tC__QrSJ-1eJXhn7L_DuAKZJjFa2d9Y4kE_96F3KWOpQ7ZhVWoAKSSgXJKG7ay2KVNJ_oZSmzZLT4uD0FKJawWlm5dM3sPCnNRey2tfXIU4SvVZeguO_ASwR1JU |
| CitedBy_id | crossref_primary_10_1016_j_genhosppsych_2023_06_019 crossref_primary_10_1016_j_genhosppsych_2024_06_012 |
| Cites_doi | 10.3820/jjpe.14.27 10.1136/bmj.h2538 10.1002/ajmg.b.31034 10.1136/pgmj.2003.017236 10.5649/jjphcs.36.863 10.3389/fphar.2014.00256 10.1038/nsmb.3198 10.1177/0269881109106927 10.1016/j.tins.2011.01.004 10.2106/JBJS.N.00724 10.1001/jama.1987.03400130103041 10.1248/yakushi.15-00235 10.1254/fpj.136.51 10.1093/sleep/23.1.1a 10.1001/jamapsychiatry.2013.3320 10.1254/fpj.119.111 10.1016/j.jcrc.2012.11.004 10.1097/CCM.0b013e318192fcf9 10.11153/jaccn.10.1_51 |
| ContentType | Journal Article |
| Copyright | 2018 The Pharmaceutical Society of Japan |
| Copyright_xml | – notice: 2018 The Pharmaceutical Society of Japan |
| CorporateAuthor | Nihon University bDepartment of Pharmacy Nihon University Itabashi Hospital Nihon University Hospital School of Pharmacy aDepartment of Pharmacy cDepartment of Pharmaceutical Regulatory Science |
| CorporateAuthor_xml | – name: aDepartment of Pharmacy – name: Nihon University Itabashi Hospital – name: School of Pharmacy – name: cDepartment of Pharmaceutical Regulatory Science – name: Nihon University – name: bDepartment of Pharmacy – name: Nihon University Hospital |
| DBID | AAYXX CITATION CGR CUY CVF ECM EIF NPM 7X8 ADTOC UNPAY |
| DOI | 10.1248/yakushi.17-00221 |
| DatabaseName | CrossRef Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed MEDLINE - Academic Unpaywall for CDI: Periodical Content Unpaywall |
| DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) MEDLINE - Academic |
| DatabaseTitleList | MEDLINE MEDLINE - Academic |
| Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database – sequence: 3 dbid: UNPAY name: Unpaywall url: https://proxy.k.utb.cz/login?url=https://unpaywall.org/ sourceTypes: Open Access Repository |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Pharmacy, Therapeutics, & Pharmacology |
| EISSN | 1347-5231 |
| EndPage | 990 |
| ExternalDocumentID | 10.1248/yakushi.17-00221 29962478 10_1248_yakushi_17_00221 cs7yakug_2018_013807_018_0985_09903111711 article_yakushi_138_7_138_17_00221_article_char_en |
| Genre | Journal Article |
| GroupedDBID | .55 123 29R 2WC ADBBV ALMA_UNASSIGNED_HOLDINGS BAWUL CS3 DIK E3Z EBS EJD F5P GX1 HH5 JMI JSF JSH MOJWN OVT P2P RJT RNS RZJ X7M XSB AAYXX CITATION 53G AFFNX CGR CUY CVF ECM EIF KQ8 LPU NPM X7J 7X8 ADTOC UNPAY |
| ID | FETCH-LOGICAL-c688t-14738e405c05d3c502bb854d163d491ca2abc9583d7ea47ee58a946ff260fa993 |
| IEDL.DBID | UNPAY |
| ISSN | 0031-6903 1347-5231 |
| IngestDate | Tue Aug 19 23:35:15 EDT 2025 Wed Oct 01 13:44:50 EDT 2025 Mon Jul 21 05:13:58 EDT 2025 Thu Apr 24 23:12:15 EDT 2025 Tue Jul 01 03:47:43 EDT 2025 Thu Jul 10 16:14:58 EDT 2025 Wed Sep 03 06:23:39 EDT 2025 |
| IsDoiOpenAccess | true |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 7 |
| Keywords | The Japanese Adverse Drug Event Report delirium reporting odds ratio |
| Language | English Japanese |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c688t-14738e405c05d3c502bb854d163d491ca2abc9583d7ea47ee58a946ff260fa993 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 |
| OpenAccessLink | https://proxy.k.utb.cz/login?url=https://www.jstage.jst.go.jp/article/yakushi/138/7/138_17-00221/_pdf |
| PMID | 29962478 |
| PQID | 2063711825 |
| PQPubID | 23479 |
| PageCount | 6 |
| ParticipantIDs | unpaywall_primary_10_1248_yakushi_17_00221 proquest_miscellaneous_2063711825 pubmed_primary_29962478 crossref_primary_10_1248_yakushi_17_00221 crossref_citationtrail_10_1248_yakushi_17_00221 medicalonline_journals_cs7yakug_2018_013807_018_0985_09903111711 jstage_primary_article_yakushi_138_7_138_17_00221_article_char_en |
| ProviderPackageCode | CITATION AAYXX |
| PublicationCentury | 2000 |
| PublicationDate | 2018-07-01 |
| PublicationDateYYYYMMDD | 2018-07-01 |
| PublicationDate_xml | – month: 07 year: 2018 text: 2018-07-01 day: 01 |
| PublicationDecade | 2010 |
| PublicationPlace | Japan |
| PublicationPlace_xml | – name: Japan |
| PublicationTitle | YAKUGAKU ZASSHI |
| PublicationTitleAlternate | YAKUGAKU ZASSHI |
| PublicationYear | 2018 |
| Publisher | The Pharmaceutical Society of Japan Pharmaceutical Society of Japan |
| Publisher_xml | – name: The Pharmaceutical Society of Japan – name: Pharmaceutical Society of Japan |
| References | 14) Hosomi K., Park B., Inose R., Fujimoto M., Takada M., Jpn. J. Drug Inform., 17, 125-132 (2015). 15) Nutt D. J., Stahl S. M., J. Psychopharmacol., 24, 1601-1612 (2010). 18) Hosomi K., Arai M., Fujimoto M., Takada M., Jpn. J. Drug Inform., 17, 15-20 (2015). 1) Lipowski Z. J., JAMA, 258, 1789-1792 (1987). 6) Kim K., Uchiyama M., Okawa M., Liu X., Ogihara R., Sleep, 23, 41-47 (2000). 13) Sakai T., Ohtsu F., Sekiya Y., Mori C., Sakata H., Goto N., Yakugaku Zasshi, 136, 499-505 (2016). 23) Wacker D., Roth B. L., Nat. Struct. Mol. Biol., 23, 265-266 (2016). 3) Salluh J. I., Wang H., Schneider E. B., Nagaraja N., Yenokyan G., Damluji A., Serafim R. B., Stevens R. D., BMJ, 350, h2538 (2015). 12) Hosomi K., Fujimoto M., Hachiken H., Sumitoko K., Takada M., Jpn. J. Drug Inform., 15, 147-154 (2013). 17) Vashchinkina E., Panhelainen A., Aitta-Aho T., Korpi E. R., Front. Pharmacol., 5, 256 (2014). 2) Zywiel M. G., Hurley R. T., Perruccio A. V., Hancock-Howard R. L., Coyte P. C., Rampersaud Y. R., J. Bone Joint Surg. Am., 97, 829-836 (2015). 9) Pisani M. A., Murphy T. E., Araujo K. L., Slattum P., Van Ness P. H., Inouye S. K., Crit. Care Med., 37, 177-183 (2009). 19) Shirakawa K., Nippon Yakurigaku Zasshi, 119, 111-118 (2002). 5) Alagiakrishnan K., Wiens C. A., Postgrad. Med. J., 80, 388-393 (2004). 7) Hirooka T., Jpn. J. Clin. Med., 73, 1049-1056 (2015). 4) Sasaki Y., Hayashi M., Egawa K., Koga Y., Kato E., Kinoshita Y., Utsunomiya A., Onishi J., Kuroda Y., J. Jpn. Acad. Crit. Care Nurs., 10(1), 51-62 (2014). 20) Hirai K., Kato K., Nishikawa H., Yukuhiro N., Nishiyama K., Miyamoto M., Nippon Yakurigaku Zasshi, 136, 51-60 (2010). 22) Hatta K., Kishi Y., Wada K., Takeuchi T., Odawara T., Usui C., Nakamura H., JAMA Psychiatry, 71, 397-403 (2014). 10) van Munster B. C., de Rooij S. E., Yazdanpanah M., Tienari P. J., Pitkälä K. H., Osse R. J., Adamis D., Smit O., van der Steen M. S., van Houten M., Rahkonen T., Sulkava R., Laurila J. V., Strandberg T. E., Tulen J. H., Zwang L., MacDonald A. J., Treloar A., Sijbrands E. J., Zwinderman A. H., Korevaar J. C., Am. J. Med. Genet. B Neuropsychiatr. Genet., 153B, 648-655 (2010). 16) Tan K. R., Rudolph U., Lüscher C., Trends Neurosci., 34, 188-197 (2011). 21) Yoshitaka S., Egi M., Morimatsu H., Kanazawa T., Toda Y., Morita K., J. Crit. Care, 28, 236-242 (2013). 8) Nakajima M., Homma M., Igarashi T., Kambayashi Y., Ohara M., Nagasawa I., Kohda Y., Jpn. J. Pharm. Health Care Sci., 36, 863-867 (2010). 11) Fujita T., Jpn. J. Pharmacoepidemiol., 14, 27-36 (2009). 11 22 12 23 13 14 15 16 17 18 19 1 2 3 4 5 6 7 8 9 20 10 21 |
| References_xml | – reference: 16) Tan K. R., Rudolph U., Lüscher C., Trends Neurosci., 34, 188-197 (2011). – reference: 22) Hatta K., Kishi Y., Wada K., Takeuchi T., Odawara T., Usui C., Nakamura H., JAMA Psychiatry, 71, 397-403 (2014). – reference: 3) Salluh J. I., Wang H., Schneider E. B., Nagaraja N., Yenokyan G., Damluji A., Serafim R. B., Stevens R. D., BMJ, 350, h2538 (2015). – reference: 19) Shirakawa K., Nippon Yakurigaku Zasshi, 119, 111-118 (2002). – reference: 5) Alagiakrishnan K., Wiens C. A., Postgrad. Med. J., 80, 388-393 (2004). – reference: 7) Hirooka T., Jpn. J. Clin. Med., 73, 1049-1056 (2015). – reference: 23) Wacker D., Roth B. L., Nat. Struct. Mol. Biol., 23, 265-266 (2016). – reference: 17) Vashchinkina E., Panhelainen A., Aitta-Aho T., Korpi E. R., Front. Pharmacol., 5, 256 (2014). – reference: 8) Nakajima M., Homma M., Igarashi T., Kambayashi Y., Ohara M., Nagasawa I., Kohda Y., Jpn. J. Pharm. Health Care Sci., 36, 863-867 (2010). – reference: 4) Sasaki Y., Hayashi M., Egawa K., Koga Y., Kato E., Kinoshita Y., Utsunomiya A., Onishi J., Kuroda Y., J. Jpn. Acad. Crit. Care Nurs., 10(1), 51-62 (2014). – reference: 11) Fujita T., Jpn. J. Pharmacoepidemiol., 14, 27-36 (2009). – reference: 10) van Munster B. C., de Rooij S. E., Yazdanpanah M., Tienari P. J., Pitkälä K. H., Osse R. J., Adamis D., Smit O., van der Steen M. S., van Houten M., Rahkonen T., Sulkava R., Laurila J. V., Strandberg T. E., Tulen J. H., Zwang L., MacDonald A. J., Treloar A., Sijbrands E. J., Zwinderman A. H., Korevaar J. C., Am. J. Med. Genet. B Neuropsychiatr. Genet., 153B, 648-655 (2010). – reference: 2) Zywiel M. G., Hurley R. T., Perruccio A. V., Hancock-Howard R. L., Coyte P. C., Rampersaud Y. R., J. Bone Joint Surg. Am., 97, 829-836 (2015). – reference: 21) Yoshitaka S., Egi M., Morimatsu H., Kanazawa T., Toda Y., Morita K., J. Crit. Care, 28, 236-242 (2013). – reference: 12) Hosomi K., Fujimoto M., Hachiken H., Sumitoko K., Takada M., Jpn. J. Drug Inform., 15, 147-154 (2013). – reference: 14) Hosomi K., Park B., Inose R., Fujimoto M., Takada M., Jpn. J. Drug Inform., 17, 125-132 (2015). – reference: 18) Hosomi K., Arai M., Fujimoto M., Takada M., Jpn. J. Drug Inform., 17, 15-20 (2015). – reference: 20) Hirai K., Kato K., Nishikawa H., Yukuhiro N., Nishiyama K., Miyamoto M., Nippon Yakurigaku Zasshi, 136, 51-60 (2010). – reference: 9) Pisani M. A., Murphy T. E., Araujo K. L., Slattum P., Van Ness P. H., Inouye S. K., Crit. Care Med., 37, 177-183 (2009). – reference: 15) Nutt D. J., Stahl S. M., J. Psychopharmacol., 24, 1601-1612 (2010). – reference: 13) Sakai T., Ohtsu F., Sekiya Y., Mori C., Sakata H., Goto N., Yakugaku Zasshi, 136, 499-505 (2016). – reference: 6) Kim K., Uchiyama M., Okawa M., Liu X., Ogihara R., Sleep, 23, 41-47 (2000). – reference: 1) Lipowski Z. J., JAMA, 258, 1789-1792 (1987). – ident: 11 doi: 10.3820/jjpe.14.27 – ident: 18 – ident: 3 doi: 10.1136/bmj.h2538 – ident: 10 doi: 10.1002/ajmg.b.31034 – ident: 5 doi: 10.1136/pgmj.2003.017236 – ident: 8 doi: 10.5649/jjphcs.36.863 – ident: 12 – ident: 17 doi: 10.3389/fphar.2014.00256 – ident: 23 doi: 10.1038/nsmb.3198 – ident: 15 doi: 10.1177/0269881109106927 – ident: 16 doi: 10.1016/j.tins.2011.01.004 – ident: 2 doi: 10.2106/JBJS.N.00724 – ident: 14 – ident: 1 doi: 10.1001/jama.1987.03400130103041 – ident: 13 doi: 10.1248/yakushi.15-00235 – ident: 20 doi: 10.1254/fpj.136.51 – ident: 6 doi: 10.1093/sleep/23.1.1a – ident: 22 doi: 10.1001/jamapsychiatry.2013.3320 – ident: 19 doi: 10.1254/fpj.119.111 – ident: 7 – ident: 21 doi: 10.1016/j.jcrc.2012.11.004 – ident: 9 doi: 10.1097/CCM.0b013e318192fcf9 – ident: 4 doi: 10.11153/jaccn.10.1_51 |
| SSID | ssib002222518 ssib002484306 ssib001136365 ssib002223935 ssib002484304 ssib002484305 ssib000959844 ssib002822080 ssib003105265 ssib023161479 ssj0023355 ssib000576198 ssib002499502 ssib003105266 ssib000937675 ssib000972830 ssib001536036 ssib002222551 ssib058494605 ssib058494604 |
| Score | 2.1360404 |
| Snippet | The Japanese Adverse Drug Event Report (JADER) database was used to examine the risk of delirium and the time of its onset with various hypnotics, including 10... |
| SourceID | unpaywall proquest pubmed crossref medicalonline jstage |
| SourceType | Open Access Repository Aggregation Database Index Database Enrichment Source Publisher |
| StartPage | 985 |
| SubjectTerms | Adverse Drug Reaction Reporting Systems Benzodiazepines - adverse effects Databases, Factual delirium Delirium - chemically induced Delirium - epidemiology Humans Hypnotics and Sedatives - adverse effects Japan - epidemiology Odds Ratio reporting odds ratio Risk The Japanese Adverse Drug Event Report Time Factors |
| Title | Assessment of the Relationship between Hypnotics and Delirium Using the Japanese Adverse Drug Event Report (JADER) Database |
| URI | https://www.jstage.jst.go.jp/article/yakushi/138/7/138_17-00221/_article/-char/en http://mol.medicalonline.jp/library/journal/download?GoodsID=cs7yakug/2018/013807/018&name=0985-0990e https://www.ncbi.nlm.nih.gov/pubmed/29962478 https://www.proquest.com/docview/2063711825 https://www.jstage.jst.go.jp/article/yakushi/138/7/138_17-00221/_pdf |
| UnpaywallVersion | publishedVersion |
| Volume | 138 |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| ispartofPNX | YAKUGAKU ZASSHI, 2018/07/01, Vol.138(7), pp.985-990 |
| journalDatabaseRights | – providerCode: PRVFSB databaseName: Free Full-Text Journals in Chemistry customDbUrl: eissn: 1347-5231 dateEnd: 99991231 omitProxy: true ssIdentifier: ssj0023355 issn: 0031-6903 databaseCode: HH5 dateStart: 18810101 isFulltext: true titleUrlDefault: http://abc-chemistry.org/ providerName: ABC ChemistRy – providerCode: PRVBFR databaseName: Free Medical Journals customDbUrl: eissn: 1347-5231 dateEnd: 99991231 omitProxy: true ssIdentifier: ssj0023355 issn: 0031-6903 databaseCode: DIK dateStart: 19470101 isFulltext: true titleUrlDefault: http://www.freemedicaljournals.com providerName: Flying Publisher – providerCode: PRVFQY databaseName: GFMER Free Medical Journals customDbUrl: eissn: 1347-5231 dateEnd: 99991231 omitProxy: true ssIdentifier: ssj0023355 issn: 0031-6903 databaseCode: GX1 dateStart: 0 isFulltext: true titleUrlDefault: http://www.gfmer.ch/Medical_journals/Free_medical.php providerName: Geneva Foundation for Medical Education and Research |
| link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV3da9swEBddOtjK2PdH9lE0GGUddRLbsiW9LSwtWcZKGA20T0KW5TRtapskZmT753eybGcdY2PsJcqDdJx0Z93vuNMdQm8o5QrcBnBLuC8dIj3icBYpx6SzUZ1IPylbJ3w-DocTMjoNTrfQoH4LY9IqLwAXTbUZOtOsc5F3q0PsruVlsTyHL91nXWp-BVyxxgq5XZHHyQ20HQaAyFtoe3I87p_ZiowusFE2SDaPJo3f5VbRSo-wmmKnpnPNOt20jOygO1c2aGKLV_wOi-6gW0Way_VXOZ__ZJ-O7iFd78ympVx2ilXUUd9-Kfr4v1u_j-5WABb37YoHaEunD9He2FbAXh_gk82DruUB3sPjTW3s9SP0vd9UAsVZggF94iYd73yW4yptDA_XeZoZElimMR7o-WwxK65wmeBQrhqBkTfNM3HZURrGwaKY4kOTvYmtU4HfjkDLvuzjgVxJY6wfo8nR4cmHoVP1f3BUyNjKcQn1mQZEqXpB7Kug50URC0gMEDIm3FXSk5HiAfNjqiWhWgdMchImCfhoiQTg9QS10izVzxCWjHAvktpnskckdaWKYwUDgFkecx63UbeWu1BVcXTTo2MujJMEmiIqAcCxi_LY22i_WZHbwiB_mNu3gm1mVmLdzASBUmHFatc0U8zrO7jC2uj9NS0U1V2zFGpJDZmpACzHhIk894CG-ctZIEzg0weDRl1g43WtuAIuERMZAkllxRJWhj41rmbQRk-tRjesAl4JPUJZG71rVPyvO37-L5NfoNuGdZsE_RK1VotCvwKot4p2wcn5-Gm3-p5_AC-WUsQ |
| linkProvider | Unpaywall |
| linkToUnpaywall | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV3da9swED-6dLCVse-P7AsNRllHncS2bMlvC0tLCKyE0UD3JGRZTtOmjkliRrZ_fifLdtYxNsZeojxIx0l31v2OO90BvGUsUug2oFsS-dKh0qNOxGPlmHQ2plPpp2XrhE8n4XBCR2fB2Q4M6rcwJq3yAnHRVJuhM110LvJudYjdjbwsVuf4pfu8y8yvwCvWWCG3K_IkvQG7YYCIvAW7k5Nx_4utyOgiG2WDZPNo0vhdbhWt9CivKXZqOtes003LyB7cubJBE1u84ndYdA9uFVkuN1_lfP6TfTq-B7remU1LuewU67ijvv1S9PF_t34f7lYAlvTtigewo7OHsD-2FbA3h-R0-6BrdUj2yXhbG3vzCL73m0qgZJESRJ-kScc7n-WkShsjw02eLQwJIrOEDPR8tpwVV6RMcChXjdDIm-aZpOwojeNgWUzJkcneJNapIO9GqGWfD8hArqUx1o9hcnx0-nHoVP0fHBVyvnZcynyuEVGqXpD4Kuh5ccwDmiCETGjkKunJWEUB9xOmJWVaB1xGNExT9NFSicDrCbSyRaafAZGcRl4stc9lj0rmSpUkCgcEs1ESRUkburXchaqKo5seHXNhnCTUFFEJAI9dlMfehoNmRW4Lg_xhbt8KtplZiXU7EwXKhBWrXdNMMa_v8Aprw4drWiiqu2Yl1IoZMlOBWI4LE3nuIQ3zN-KBMIFPHw0ac5GNN7XiCrxETGQIJbUoVrgy9JlxNYM2PLUa3bCKeCX0KONteN-o-F93_PxfJr-A24Z1mwT9ElrrZaFfIdRbx6-rL_kHRKVRyw |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Assessment+of+the+Relationship+between+Hypnotics+and+Delirium+Using+the+Japanese+Adverse+Drug+Event+Report+%28JADER%29+Database&rft.jtitle=Yakugaku+zasshi&rft.au=Kikuchi%2C+Norikazu&rft.au=Hazama%2C+Katsuyuki&rft.au=Imai%2C+Toru&rft.au=Suzuki%2C+Shinichiro&rft.date=2018-07-01&rft.issn=0031-6903&rft.eissn=1347-5231&rft.volume=138&rft.issue=7&rft.spage=985&rft.epage=990&rft_id=info:doi/10.1248%2Fyakushi.17-00221&rft.externalDBID=n%2Fa&rft.externalDocID=10_1248_yakushi_17_00221 |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0031-6903&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0031-6903&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0031-6903&client=summon |